O'Reilly R A
N Engl J Med. 1976 Aug 12;295(7):354-7. doi: 10.1056/NEJM197608122950702.
Because of the known interaction of warfarin and disulfiram and the "disulfiram effect" of metronidazole, the interaction with metronidazole of commercial racemic warfarin and its separated enantiomorphs was evaluated in eight normal subjects. Single oral doses of racemate, S(-)-warfarin, and R (+)-warfarin, were administered in the amounts of 1.5, 0.75 and 1.5 mg per kilogram of body weight, respectively, with and without metronidazole, 750 mg by mouth, beginning seven days before the warfarin dose and continuing seven days before the warfarin dose and continuing daily throughout the hypoprothrombinemia. Daily plasma samples were analyzed for warfarin in content and one-stage prothrombin time. A highly significant (P less than 0.01) augmentation of the mean warfarin level and hypoprothrombinemia with metronidazole occurred for racemic and S (-)-warfarin; none occurred with R (+)-warfarin. Thus, the interaction of racemic warfarin and metronidazole is stereoselective and can be lessened or even avoided by use of R (+)-warfarin alone for long-term therapy.
由于已知华法林与双硫仑之间的相互作用以及甲硝唑的“双硫仑样效应”,在8名正常受试者中评估了市售消旋华法林及其分离对映体与甲硝唑之间的相互作用。分别以每千克体重1.5、0.75和1.5毫克的剂量口服给予消旋体、S(-)-华法林和R(+)-华法林单剂量,同时服用或不服用750毫克口服甲硝唑,从华法林给药前7天开始,持续至华法林给药前7天,并在整个低凝血酶原血症期间每日服用。每天采集血浆样本分析华法林含量和一期凝血酶原时间。对于消旋体和S(-)-华法林,甲硝唑使平均华法林水平和低凝血酶原血症显著升高(P小于0.01);而R(+)-华法林则未出现这种情况。因此,消旋华法林与甲硝唑之间的相互作用具有立体选择性,长期治疗单独使用R(+)-华法林可减轻甚至避免这种相互作用。